Work

Pulmonary Arterial Hypertension – Future Directions

Year: 2007

Type: article

Abstract: Pulmonary arterial hypertension (PAH) is a rare but life-threatening condition that has traditionally required treatment with continuous intravenous epoprostenol via an indwelling central catheter.1–3 Such therapy improves outcome, but is fraught with side effects, expense, and risk of catheter-related complications.

Source: European Cardiology Review

DOI: 10.15420/ecr.2007.0.2.78

Author: Robert P Frantz

Institution: Mayo Clinic

Language: English

Topic: Pulmonary Hypertension Research and Treatments

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $2,146